The Oncology Service – Richmond
  • Phone: 804-999-0001
  • Our Services
    • Medical Oncology
    • Radiation Oncology
    • Stereotactic Radiation Therapy
    • Diagnostic Imaging
  • For Your Pet
    • Client Registration Form
    • COVID Curb-Side Procedures
    • When Your Pet is a Patient
    • Your First Visit
    • Client Portal
    • FAQ
    • Pet Insurance
    • Grief Resources
    • Clinical Studies
  • For Veterinary Teams
    • COVID-19 Hospital Updates
    • Referral Forms and Portal
    • At a Glance
    • Ethos Materials for Clinics
    • Continuing Education
    • VetBloom CE
    • Clinical Studies
  • About Us
    • Our Hospital
    • Our Team
    • Why Ethos
    • Ethos Discovery
    • Contact Us
  • Blogs & Videos
    • Our Blogs
    • PAWEDcasts
  • We’re Hiring!
    • Apply Today
    • Benefits and Perks
    • Veterinary Training Programs
The Oncology Service – Richmond
  • Our Services
    • Medical Oncology
    • Radiation Oncology
    • Stereotactic Radiation Therapy
    • Diagnostic Imaging
  • For Your Pet
    • Client Registration Form
    • COVID Curb-Side Procedures
    • When Your Pet is a Patient
    • Your First Visit
    • Client Portal
    • FAQ
    • Pet Insurance
    • Grief Resources
    • Clinical Studies
  • For Veterinary Teams
    • COVID-19 Hospital Updates
    • Referral Forms and Portal
    • At a Glance
    • Ethos Materials for Clinics
    • Continuing Education
    • VetBloom CE
    • Clinical Studies
  • About Us
    • Our Hospital
    • Our Team
    • Why Ethos
    • Ethos Discovery
    • Contact Us
  • Blogs & Videos
    • Our Blogs
    • PAWEDcasts
  • We’re Hiring!
    • Apply Today
    • Benefits and Perks
    • Veterinary Training Programs
  • Phone: 804-999-0001

Clinical Studies

  • Evaluating the Tolerability of Combination of Verdinexor and Doxorubicin in Dogs with Cancer

    Currently Enrolling

    Verdinexor is a chemotherapy drug that has been conditionally approved by the FDA for the treatment of canine lymphoma. Verdinexor is a selective inhibitor of nuclear export (SINE) compound, and this family of drug has demonstrated encouraging results in preclinical studies when combined with other chemotherapeutic drugs.

    Study Details
  • Trial Evaluating an Investigational Agent for Management of Transitional Cell Carcinoma

    Closed

    This trial is designed to evaluate the safety and preliminary pain management and anti-cancer effectiveness of a novel therapy in dogs with bladder transitional cell carcinoma (TCC).

    Study Details
The Oncology Service – Richmond
804-999-0001 | 5711 Staples Mill Road # 102 
  • Phone: 804-999-0001
  • Our Services
    • Medical Oncology
    • Radiation Oncology
    • Stereotactic Radiation Therapy
    • Diagnostic Imaging
  • For Your Pet
    • Client Registration Form
    • COVID Curb-Side Procedures
    • When Your Pet is a Patient
    • Your First Visit
    • Client Portal
    • FAQ
    • Pet Insurance
    • Grief Resources
    • Clinical Studies
  • For Veterinary Teams
    • COVID-19 Hospital Updates
    • Referral Forms and Portal
    • At a Glance
    • Ethos Materials for Clinics
    • Continuing Education
    • VetBloom CE
    • Clinical Studies
  • About Us
    • Our Hospital
    • Our Team
    • Why Ethos
    • Ethos Discovery
    • Contact Us
  • Blogs & Videos
    • Our Blogs
    • PAWEDcasts
  • We’re Hiring!
    • Apply Today
    • Benefits and Perks
    • Veterinary Training Programs
© 2022 The Oncology Service – Richmond
Website Design by Jackrabbit